Join the 'Pasireotide' group to help and get support from people like you.
Posted 16 Dec 2014 by Drugs.com
EAST HANOVER, N.J., Dec. 16, 2014 Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor long-acting release (LAR)* (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. The approval of Signifor LAR, a next-generation somatostatin analog (SSA), helps address a critical unmet need among the acromegaly patient population. Signifor LAR has been studied and found effective in both medically naive patients with acromegaly who have had prior surgery or for whom surgery was not an option, as well as patients whose disease is not fully controlled on first generation SSAs2. Acromegaly is a rare, debilitating endocrine disorder caused by the excess production of growth hormone (GH) and insulin-like growth factor-1 ... Read more